CAM

PF3D7_1434200 (CAM) is the single-copy calmodulin of Plasmodium falciparum, a Ca2+-dependent sensor expressed throughout the erythrocytic cycle that couples calcium signals to multiple downstream effectors controlling merozoite invasion, calcium homeostasis, and early intraerythrocytic development (PMID:3313391, PMID:8720124, PMID:26689736). It is encoded by one gene on chromosome 14 with a single intron and is highly homologous to eukaryotic calmodulins, with peak mRNA at the trophozoite/schizont transition and protein regulated at both transcriptional and mRNA-stability levels (PMID:1852174, PMID:8720124). CAM localizes diffusely in the parasite cytoplasm and concentrates at the apical end of merozoites, where its function is required for erythrocyte invasion — calmodulin antagonists block invasion and schizont maturation (PMID:3313391, PMID:3127214, PMID:18762219). Mechanistically, CAM binds calcium and, in a Ca2+-dependent manner, activates a set of effectors: it binds and activates protein kinase B (PfPKB) through a mapped N-terminal CAM-binding domain, functioning downstream of phospholipase C-driven Ca2+ release and upstream of glideosome phosphorylation and the actin-myosin motor during invasion (PMID:16809343, PMID:18165240); it activates the PP2B-like phosphatase calcineurin and the calcium-dependent phosphatase PP7 within a calcium-signaling complex that controls ring-stage development (PMID:10340482, PMID:39387582); and it supports CaMK-type kinase (PfPK2) activity (PMID:18762219). CAM also modulates cytosolic calcium levels and calcium-dependent proteolysis, and its inhibition mobilizes Ca2+ from acidic intracellular stores (PMID:29913151, PMID:26689736). Structurally, Ca2+-saturated CAM binds target peptides through an ensemble of co-existing conformations that lack a single classical anchoring interaction, and its C-terminal domain is more thermally stable than that of human calmodulin, though these differences are insufficient to make it a selective drug target (PMID:32821880, PMID:36906144).

1. 1987 Medium

   Established that CAM is present in the parasite, accumulates with maturation, and is positioned at the merozoite apex where invasion machinery acts, linking it to the calcium requirement of invasion.

   Evidence Radioimmunoassay and immunoelectron microscopy in free and intraerythrocytic P. falciparum, with calmodulin-antagonist inhibition of invasion and schizont maturation

   PMID:3127214 PMID:3313391

   Open questions at the time

   • Antagonist effects are pharmacological and not gene-specific loss-of-function
   • No direct molecular effector identified at this stage
2. 1991 Medium

   Defined CAM as a single-copy, single-intron gene on chromosome 14 highly homologous to eukaryotic calmodulins, and excluded a role in chloroquine resistance.

   Evidence Southern blotting, DNA sequencing, primer extension, and Western blotting comparing resistant and sensitive isolates

   PMID:1852174 PMID:1915742

   Open questions at the time

   • Gene structure alone does not establish function
   • Sequence homology does not confirm shared regulatory partners
3. 1995 Medium

   Showed CAM expression is stage-regulated with a trophozoite/schizont peak and controlled by mRNA stability, indicating it is not a constitutive housekeeping product but tied to a specific developmental window.

   Evidence Northern, Western, and pulse-chase RNA stability assays across the erythrocytic cycle

   PMID:8720124

   Open questions at the time

   • Regulatory factors controlling mRNA degradation not identified
   • Functional consequence of the expression peak not tested directly
4. 1999 Medium

   Identified the first defined enzymatic effector by showing CAM plus Ca2+ activates the parasite PP2B-like calcineurin, placing CAM at the head of a phosphatase-signaling axis.

   Evidence Enzyme purification and phosphatase activity assays with cyclosporin A and wild-type versus mutant cyclophilin controls

   PMID:10340482

   Open questions at the time

   • Cellular substrates of calcineurin downstream of CAM not mapped
   • In vitro activation not linked to a phenotype
5. 2005 Medium

   Characterized the CAM promoter architecture and poly(dA)·poly(dT)-dependent nuclear factor binding driving its transcription.

   Evidence TSS mapping, promoter-deletion reporter assays, and EMSA of the pfcam 5' flanking region

   PMID:15850701

   Open questions at the time

   • Specific transcription factors binding the promoter not identified
   • Relationship to stage-specific expression not resolved
6. 2006 Medium

   Established a direct Ca2+-dependent CAM–PfPKB signaling module and mapped the CAM-binding domain, defining PLC as upstream and CAM as the activator of a specific parasite kinase.

   Evidence Reciprocal co-immunoprecipitation, in vitro kinase assay, domain mapping, and PLC pharmacological inhibition

   PMID:16809343

   Open questions at the time

   • In vivo requirement for the CAM–PfPKB interaction not tested genetically
   • Full substrate set of PfPKB not defined here
7. 2007 Medium

   Connected the CAM–PfPKB cascade to the invasion machinery, showing it feeds into glideosome phosphorylation and the actin-myosin motor.

   Evidence Calmodulin/PLC pharmacological inhibition, invasion assays, in vitro kinase assay, and Co-IP with the motor complex (PfGAP45)

   PMID:18165240

   Open questions at the time

   • Inhibitor-based; no CAM-specific genetic knockout of invasion
   • Direct CAM contact with the motor not distinguished from kinase-mediated effect
8. 2008 Medium

   Extended CAM's kinase-activation role by showing it drives Ca2+-dependent activity of a CaMK homolog (PfPK2) linked to invasion, and confirmed merozoite localization at rupture/release.

   Evidence Immunoelectron microscopy, recombinant PfPK2 purification, in vitro kinase assay, and invasion inhibition

   PMID:18762219

   Open questions at the time

   • Physiological substrates of PfPK2 in the parasite not established
   • Contribution of PfPK2 relative to PfPKB not quantified
9. 2015 Medium

   Demonstrated CAM's role in calcium homeostasis by showing its inhibition mobilizes Ca2+ from acidic (non-ER) stores and modulates plasma membrane Ca2+ channels.

   Evidence Knockin transgenic expression and fluorometric Ca2+ imaging with pharmacological dissection

   PMID:26689736

   Open questions at the time

   • Molecular identity of the acidic-store Ca2+ machinery not defined
   • Effects rely on the CAM inhibitor calmidazolium rather than genetic ablation
10. 2018 Medium

    Provided gain-of-function evidence that CAM modulates cytosolic Ca2+ dynamics and calcium-dependent proteolysis in the erythrocytic parasite.

    Evidence Transgenic overexpression with fluorometric Ca2+ measurement and fluorogenic protease activity assay

    PMID:29913151

    Open questions at the time

    • Protease targets of the CAM-linked proteolytic activity not identified
    • Overexpression may not reflect endogenous stoichiometry
11. 2020 Medium

    Biophysically characterized recombinant CAM, showing near-human enzyme-activation behavior but a more thermally stable C-terminal domain, and evaluated it as a drug target.

    Evidence Thermal stability, fluorescence, CD, in vitro enzyme activation, and Malaria Box inhibitor binding assays

    PMID:32821880

    Open questions at the time

    • Differences from human CaM judged insufficient for selectivity
    • In vitro assays not linked to parasite phenotype
12. 2023 High

    Resolved the structural basis of CAM target recognition, showing Ca2+-saturated CAM binds peptides through an ensemble of conformers lacking classical anchoring, explaining its nanomolar affinity.

    Evidence X-ray crystallography of Ca2+-saturated CAM–melittin complexes and molecular dynamics simulations

    PMID:36906144

    Open questions at the time

    • Melittin is a model peptide, not a physiological CAM target
    • Conformational ensemble not confirmed for native effectors like PfPKB
13. 2024 Medium

    Placed CAM in a calcium-signaling complex with the calcium-dependent phosphatase PP7 and CDPK1 that governs early ring-stage development.

    Evidence Conditional DiCre disruption, phosphoproteomics, Co-IP/mass spectrometry, and in vitro phosphatase assay

    PMID:39387582

    Open questions at the time

    • Direct CAM–PP7 binding interface not mapped
    • CAM's specific contribution to the phenotype not isolated from PP7/CDPK1
14. 2022 Low

    Proposed CAM as a candidate myosin regulatory light chain by showing it binds the MyoB IQ2 motif in vitro.

    Evidence In vitro pulldown/binding assay with four putative regulatory light chains

    PMID:36273584

    Open questions at the time

    • Single in vitro pulldown with no CAM-specific functional follow-up
    • In vivo role of CAM as a MyoB light chain unestablished
15. 2026 Low

    Predicted CAM as a regulatory light chain for the processive class XXII myosin PfMyoF in perinuclear membrane trafficking.

    Evidence Structural prediction of up to six CAM copies binding the PfMyoF neck plus biochemical MyoF motor characterization

    PMID:42141018

    Open questions at the time

    • CAM–MyoF binding is a structural prediction without direct biochemical confirmation
    • Functional consequence of CAM binding for MyoF activity untested

• It remains unknown whether CAM is genetically essential and how its distinct effector arms (kinases, phosphatases, myosin light-chain roles) are prioritized during invasion versus ring-stage development, since almost all functional evidence rests on pharmacological inhibition or overexpression rather than clean loss-of-function.
• No CAM-specific gene disruption phenotype reported
• Relative in vivo importance of each effector not quantified
• Physiological CAM target peptides not structurally resolved